EphB2, a member of the Eph receptor tyrosine kinase family, plays critical roles in various cellular processes, particularly during development and in the adult nervous system. This transmembrane receptor is primarily involved in mediating cell-cell communication through bidirectional signaling upon interaction with its ligands, the ephrins. In the central nervous system, EphB2 regulates axon guidance, synaptic plasticity, and spine morphology, contributing to the establishment and refinement of neural circuits. Additionally, EphB2 is implicated in the regulation of cell migration, adhesion, and proliferation in various tissues and organs, highlighting its diverse functions beyond the nervous system. Activation of EphB2 typically occurs through ligand-induced receptor clustering, leading to autophosphorylation of specific tyrosine residues within the intracellular domain, thereby initiating downstream signaling cascades.
The activation of EphB2 triggers multiple intracellular signaling pathways, including the Ras-MAPK, PI3K-Akt, and Rho GTPase pathways, among others. Upon phosphorylation, EphB2 recruits cytoplasmic adaptor proteins and kinases, such as Grb2, Src, and FAK, which serve as intermediaries in propagating signals to downstream effectors. These pathways converge to regulate diverse cellular processes, such as cytoskeletal remodeling, gene expression, and cell survival. Notably, EphB2 activation can also induce bidirectional signaling, influencing the behavior of both the receptor-expressing cell and its ligand-expressing counterparts. Through its ability to modulate cell-cell interactions and intracellular signaling, EphB2 activation plays pivotal roles in various physiological and pathological conditions, ranging from neuronal development to cancer progression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Anastrozole is an aromatase inhibitor that can decrease estrogen levels. Reduced estrogen can indirectly activate EphB2 expression in estrogen-responsive tissues. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that may activate EphB2 signaling, as EGFR and EphB2 pathways can interact, especially in cancer cells. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, another EGFR inhibitor, can similarly activate EphB2 activity through its effect on EGFR, which may intersect with EphB2 pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual EGFR and HER2 inhibitor, can potentially activate EphB2 activity in the context of cancer biology where these pathways intersect. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases and could indirectly activate EphB2 signaling, particularly in cancerous tissues. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that may activate EphB2 activity by modulating related signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, known for targeting BCR-ABL, c-KIT, and PDGFR, could activate EphB2 through its broad kinase inhibition profile. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, an estrogen receptor modulator, could activate EphB2 activity indirectly in estrogen-responsive tissues. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF1120, targeting VEGFR, PDGFR, and FGFR, might influence EphB2 indirectly, especially in angiogenesis and cancer progression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, could activate EphB2 signaling, considering JAK-STAT pathway's role in various biological processes. | ||||||